These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38266915)

  • 1. Evaluating Utilization of Tiny-TIM to Assess the Effect of Food on the Absorptions of Oral Drugs and Its Application on Biopharmaceutical Modeling.
    Liu J; Nagapudi K; Chiang PC
    J Pharm Sci; 2024 Jun; 113(6):1586-1596. PubMed ID: 38266915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilizing Tiny-TIM to Assess the Effect of Acid-Reducing Agents on the Absorption of Orally Administered Drugs.
    Liu J; Nagapudi K; Dolton MJ; Chiang PC
    J Pharm Sci; 2021 Aug; 110(8):3020-3026. PubMed ID: 33940027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the IVIVC by Combining Tiny-tim Outputs and Compartmental PK Model to Predict Oral Exposure for Different Formulations of Ibuprofen.
    Chiang PC; Liu J; Nagapudi K; Wu R; Dolton MJ; Salehi N; Amidon G
    J Pharm Sci; 2022 Jul; 111(7):2018-2029. PubMed ID: 35120962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of tiny-TIM as a mechanistic tool to investigate the in vitro performance of different itraconazole formulations under physiologically relevant conditions.
    López Mármol Á; Fischer PL; Wahl A; Schwöbel D; Lenz V; Sauer K; Koziolek M
    Eur J Pharm Sci; 2022 Jun; 173():106165. PubMed ID: 35278610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using Tiny-TIM Dissolution and In Silico Simulation to Accelerate Oral Product Development of a BCS Class II Compound.
    Luo L; Thakral NK; Schwabe R; Li L; Chen S
    AAPS PharmSciTech; 2022 Jul; 23(6):185. PubMed ID: 35778639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of two dynamic in vitro models simulating fasted and fed state conditions in the upper gastrointestinal tract (TIM-1 and tiny-TIM) for investigating the bioaccessibility of pharmaceutical compounds from oral dosage forms.
    Verwei M; Minekus M; Zeijdner E; Schilderink R; Havenaar R
    Int J Pharm; 2016 Feb; 498(1-2):178-86. PubMed ID: 26688035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral biopharmaceutics tools: recent progress from partnership through the Pharmaceutical Education and Research with Regulatory Links collaboration.
    O'Dwyer PJ; Box KJ; Dressman J; Griffin BT; Henze LJ; Litou C; Pentafragka C; Statelova M; Vertzoni M; Reppas C
    J Pharm Pharmacol; 2021 Mar; 73(4):437-446. PubMed ID: 33793836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating Dynamic in vitro Systems and Mechanistic Absorption Modeling: Case Study of Pralsetinib.
    Dolton MJ; Bowman C; Ma F; Cheeti S; Kuruvilla D; Kassir N; Chen Y; Liu J; Chiang PC
    J Pharm Sci; 2024 Sep; 113(9):2952-2956. PubMed ID: 39002726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
    Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
    Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vivo Predictive Dissolution (IPD) and Biopharmaceutical Modeling and Simulation: Future Use of Modern Approaches and Methodologies in a Regulatory Context.
    Lennernäs H; Lindahl A; Van Peer A; Ollier C; Flanagan T; Lionberger R; Nordmark A; Yamashita S; Yu L; Amidon GL; Fischer V; Sjögren E; Zane P; McAllister M; Abrahamsson B
    Mol Pharm; 2017 Apr; 14(4):1307-1314. PubMed ID: 28195732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
    Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
    Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs.
    Bergström CA; Holm R; Jørgensen SA; Andersson SB; Artursson P; Beato S; Borde A; Box K; Brewster M; Dressman J; Feng KI; Halbert G; Kostewicz E; McAllister M; Muenster U; Thinnes J; Taylor R; Mullertz A
    Eur J Pharm Sci; 2014 Jun; 57():173-99. PubMed ID: 24215735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional intestinal drug permeation: biopharmaceutics and drug development.
    Lennernäs H
    Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Food Effect Projections via Physiologically Based Pharmacokinetic Modeling: Predictive Case Studies.
    Tistaert C; Heimbach T; Xia B; Parrott N; Samant TS; Kesisoglou F
    J Pharm Sci; 2019 Jan; 108(1):592-602. PubMed ID: 29906472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Abrahamsson B; Brewster M; Brouwers J; Butler J; Carlert S; Dickinson PA; Dressman J; Holm R; Klein S; Mann J; McAllister M; Minekus M; Muenster U; Müllertz A; Verwei M; Vertzoni M; Weitschies W; Augustijns P
    Eur J Pharm Sci; 2014 Jun; 57():342-66. PubMed ID: 23988843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and applications of a physiologically-based model of paediatric oral drug absorption.
    Johnson TN; Bonner JJ; Tucker GT; Turner DB; Jamei M
    Eur J Pharm Sci; 2018 Mar; 115():57-67. PubMed ID: 29309876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo methods for drug absorption - comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects.
    Sjögren E; Abrahamsson B; Augustijns P; Becker D; Bolger MB; Brewster M; Brouwers J; Flanagan T; Harwood M; Heinen C; Holm R; Juretschke HP; Kubbinga M; Lindahl A; Lukacova V; Münster U; Neuhoff S; Nguyen MA; Peer Av; Reppas C; Hodjegan AR; Tannergren C; Weitschies W; Wilson C; Zane P; Lennernäs H; Langguth P
    Eur J Pharm Sci; 2014 Jun; 57():99-151. PubMed ID: 24637348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS/BDDCS Class II drug nifedipine.
    Patel N; Polak S; Jamei M; Rostami-Hodjegan A; Turner DB
    Eur J Pharm Sci; 2014 Jun; 57():240-9. PubMed ID: 24060671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.